- $54.51m
- $51.55m
- CA$15.56m
Immunoprecise Antibodies Ltd expected to post a loss of 5 cents a share - Earnings Preview
Brief: Immunoprecise Validates Lensai Epitope Mapping Platform Across Broad Range Of Unseen Therapeutic Targets Beyond Training Data
U.S. STOCKS ON THE MOVE-Moderna, Cardinal Health, Adobe
U.S. STOCKS ON THE MOVE-CureVac, Conagra, Oklo
U.S. STOCKS ON THE MOVE-Esty, America's Car-Mart, ImmunoPrecise
Brief: ImmunoPrecise Antibodies Says AI-Designed GLP-1 Peptides Surpass Semaglutide In Receptor Activation
ImmunoPrecise jumps after AI peptides beat semaglutide in lab tests
Brief: Immunoprecise Announces Ai-Driven Breakthrough In Universal Dengue Vaccine Discovery
Immunoprecise Antibodies Ltd reports results for the quarter ended January 31 - Earnings Summary
Brief: Immunoprecise Antibodies (IPA) Reports Financial Results And Recent Business Highlights For Third Quarter Fiscal Year 2025
Immunoprecise Antibodies Ltd expected to post a loss of 8 cents a share - Earnings Preview
Immunoprecise Antibodies Ltd expected to post a loss of 8 cents a share - Earnings Preview
Brief: Immunoprecise Antibodies Announces Transfer To Nasdaq Capital Market And Extension Of Bid Price Compliance Period
U.S. STOCKS ON THE MOVE-SmartFinancial, TE Connectivity, Arista Networks
ImmunoPrecise Antibodies jumps on AI-powered diabetes treatment
Brief: IPA Announces Resignation Of Chief Financial Officer
Immunoprecise Antibodies Ltd reports results for the quarter ended October 31 - Earnings Summary
Immunoprecise Antibodies Ltd expected to post a loss of 9 cents a share - Earnings Preview
Brief: Immunoprecise Antibodies Advances Therapeutic Innovation With Groundbreaking Rabbit Antibody Developments